The article presents the research findings of influence of antioxidant compounds Enoxifol (10 mg/kg) and Mexidol (100 mg/kg) on behavior, emotional sphere and ability for self-regulation of experimental animals. The mechanism of Enoxifol and Mexidol action at high nervous functions was established on the basis of tests allowing to connect behavior reactions with the main neuromediator systems. In the “open field” test the emotional labality, stress resistance and research activity were evaluated in control rats and rats treated for three days by antioxidants. The experiments revealed that Enoxifol diminished aggressiveness, step of domination and degree of neurotic reactions of animals, increased the resistance to emotional load which was accomplished by the more firm preservation of the memory track then in intact animals. These changes in high nervous functions were caused by antiadrenergic, choline- and GABA-positive activity of Enoxifol. Mexidol in turn posessed mnemotropic effect as well, but hasn’t affected the level of stress resistance in experimental rats. Mexidol modulated acetilecholine, benzodiazepine and GABA receptors in a brain.
“open field” test, higher nervous activity, neuromediators, self-control, Enoxifol, Mexidol, antioxidants.
1. Belykh E.V., Troitskiy A.S., Khadartsev A.A., Nesmeyanov A.A. Kompleksnoe vozdeystvie Meksidola i lazernogo izlucheniya u tyazheloatletov. Klinicheskaya meditsina i farmakologiya. 2015. №2. S. 49-50.
2. Buresh Ya., Bureshova O., Kh´yuston Dzh. P. Metodiki i osnovnye eksperimenty po izucheniyu mozga i povedeniya. M.: Vysshaya shkola, 1991. 399 s.
3. Voronina T.A. Antioksidant meksidol. Osnovnye neyropsikhotropnye effekty i mekhanizm deystviya. Psikhofarmakologiya i biologicheskaya narkologiya. 2001. №1. S. 2-12.
4. Voronina T.A. Osnovnye neyropsikhotropnye effekty i mekhanizm deystviya. Farmateka. 2009. №6. S. 28-31.
5. Dyumaev K.M., Voronina T.A., Smirnov L.D. Antioksidanty v profilaktike i terapii patologii TsNS. M.: Institut biomeditsinskoy khimii RAMN, 1995. 127 s.
6. Ismaylova Kh.Yu., Agaev T.T., Semenova T.P. Individual´nye osobennosti povedeniya (mono-aminoergicheskie mekhanizmy). Baku.: Nurlan, 2007. 228 s.
7. Kaluev A.V. Tuokhimaa P. Problemy i perspektivy eksperimental´nogo modelirovaniya trevogi i depressii. Psikhofarmakologiya i biologicheskaya narkologiya. 2004. №2-3. S.1-9.
8. Kosolapov V.A., Spasov A.A., Anisimova V.A. Izuchenie antiradikal´noy aktivnosti novykh soedineniy metodom khemilyuminestsentsii. Biomeditsinskaya khimiya. 2005. №3. S. 287-294.
9. Kucheryanu V.G. Meksidol usilivaet protivoparkinsonicheskoe deystvie L-Dofa na modeli MFTP-indutsirovannogo parkinsonizma. Eksperimental´naya i klinicheskaya farmakologiya. 2001. №1. S. 22-25.
10. Mayrov O.Yu. Otsenka individual´no-tipologicheskikh osobennostey povedeniya i ustoychivosti intaktnykh krys-samtsov na osnove faktornoy modeli normal´nogo etologicheskogo spektra pokazateley v teste «otkrytoe pole». Klinicheskaya informatika i telemeditsina. 2011. № 8. S. 21-32.
11. Povedencheskie reaktsii u eksperimental´nykh zhivotnykh s razlichnoy prognosticheskoy ustoychivost´yu k stressu v teste «otkrytoe pole» / Permyakov A.A., Eliseeva E.V., Yuditskiy A.D. [i dr.]. Vestnik Udmurtskogo Universiteta. 2013. № 3. S. 83-90.
12. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. M.: Grif i K., 2012. S. 944.
13. Rukovodstvo po eksperimental´nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv. M.: Meditsina, 2005. S. 832.
14. Sarkisova K. Yu., Kulikov M.A., Kolomeytseva I.A. Vliyanie substantsii R na povedencheskie pokazateli v testakh «otkrytogo polya» i «vynuzhdennogo plavaniya» u krys s raznym tipom povedeniya. Byulleten´ eksperimental´noy biologii i meditsiny. 1996. T.121, № 3. S. 244-247.
15. Protivoishemicheskie svoystva novogo antioksidantnogo sredstva enoksifola / Spasov A.A., Kosolapov V.A., Ostrovskiy O.V. [i dr.]. Eksperimental´naya i klinicheskaya farmakologiya. 2003. №4. S. 17-20.
16. Vliyanie soedineniy s antioksidantnymi svoystvami na funktsional´nuyu aktivnost´ trombotsitov / Spasov A.A., Ostrovskiy O.V., Anisimova V.A. [i dr.]. Eksperimental´naya klinicheskaya farmakologiya. 1999. № 1. S. 38-40.
17. Farmakologiya proizvodnykh benzimidazolov / Spasov A.A., Smirnova L.A., Ozerov A.A. [i dr.]. Biomeditsinskaya khimiya. 2002. № 3. S. 252-258.
18. Sredstvo, obladayushchee protivogipoksicheskim, aktoprotektornym, nootropnym deystviem i vliyayushchee na fizicheskuyu rabotosposobnost´: pat. 2462245 Ros. Federatsiya. №2011128943(042784); zayavl. 12.07.11; opubl. 12.07.11, Byul. №27.19 s.
19. Fudin N.A., Khadartsev A.A., Nesmeyanov A.A. Vozmozhnosti aktivatsii mitokhondrial´noy aktivnosti u sportsmenov meksidolom. Vestnik novykh meditsinskikh tekhnologiy. Elektronnoe izdanie. 2015. №2. Publikatsiya 2-8. URL: http://www.medtsu.tula.ru/VNMT/Bulletin/E2015-2/5171.pdf (data obrashcheniya: 05.05.2015). DOI:https://doi.org/10.12737/11204
20. A placebo-controlled trial of acetyl-L-carnitine and α-lipoic acid in the treatment of bipolar depression / Brennan B.P., Jensen J.E., Hudson J.I. [et al.]. J. Clin. Psychopharmacol. 2013. 33(5). R. 627-635.
21. An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery / Fava M., Targum S.D., Nierenberg A.A. [et al.]. J. Psychiatr. Res. 2012. 46(12). R. 1553-1563.
22. Kaluyev A.V. Stress and grooming. M.: Aviks., 2002. R. 146.
23. Morpugo S. The effect of ambient temperature on the actions of tremorine on body temperature and on the concentration of noradrenaline, dopamine, 5-hydroxytryptamine and acetylcholine in rat brain. Br. J. Pharmac. Chemother. 1967. 31. R. 356-366.
24. Peters K.R. J. Utility of an Effect Size Analysis for Communicating Treatment Effectiveness: A Case Study of Cholinesterase Inhibitors for Alzheimer´s Disease. Am Geriatr. J Am. Geriatr. Soc. 2013. 61(7). R. 1170-1174.
25. Alzheimer disease and antioxidant therapy: How long how far? / Teixeira J., Silva T., Andrade P.B. [et al.]. Curr. Med. Chem. 2013. 20(24). R. 2939-2952.
